ArticleJournal of advanced research2026
Genetic modifications boost chrexanthomycin yield and neuroprotective potential.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChrexanthomycins, a unique class of pentangular polyphenols (PPs) conjugated with glucuronic acid, have demonstrated remarkable neuroprotective properties both in vitro and in vivo. However, their low yield has restricted their potential applications.
objectiveThis study aims to clarify the biosynthetic pathway and neuroprotective potency of chrexanthomycins, enhance their large-scale production potential, and discover novel derivatives with improved activities.
methodMultiple strategies were adopted, such as the heterologous expression of the chr gene cluster, knockout of negative regulators, overexpression of positive regulators, in vitro biochemical reactions, and deletion of tailoring enzymes to clarify the biosynthetic routine of chrexanthomycins. Caenorhabditis elegans was used to evaluate the neuroprotective potential of chrexanthomycins.
resultsThrough these approaches, we successfully elucidated the biosynthetic pathway of chrexanthomycins and significantly improved their yields by more than 10-fold in recombinant Streptomyces chrestomyceticus. Additionally, we explored the functions of hydratase ChrN and UDP-glucuronosyltransferase UGT50 in the biosynthesis of chrexanthomycins. Our efforts led to identifying a new derivative, chrexanthomycin G, which exhibited outstanding neuroprotective activities. This novel compound alleviates amyloid-β (Aβ) - induced oxidative stress, inhibits Aβ aggregation, and improves memory in C. elegans through chemotaxis tests.
conclusionsThese findings offer valuable insights into the complex mechanisms of the biosynthesis and biological activities of chrexanthomycins, laying a foundation for their potential application in treating neurodegenerative disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.